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Abstract
Background: Gα16 can activate phospholipase Cβ (PLCβ) directly like Gαq. It also couples to
tetratricopeptide repeat 1 (TPR1) which is linked to Ras activation. It is unknown whether PLCβ
and TPR1 interact with the same regions on Gα16. Previous studies on Gαq have defined two
minimal clusters of amino acids that are essential for the coupling to PLCβ. Cognate residues in
Gα16 might also be essential for interacting with PLCβ, and possibly contribute to TPR1 interaction
and other signaling events.
Results: Alanine mutations were introduced to the two amino acid clusters (246–248 and 259–
260) in the switch III region and α3 helix of Gα16. Regulations of PLCβ and STAT3 were partially
weakened by each cluster mutant. A mutant harboring mutations at both clusters generally
produced stronger suppressions. Activation of Jun N-terminal kinase (JNK) by Gα16  was
completely abolished by mutating either clusters. Contrastingly, phosphorylations of extracellular
signal-regulated kinase (ERK) and nuclear factor κB (NF-κB) were not significantly affected by these
mutations. The interactions between the mutants and PLCβ2 and TPR1 were also reduced in co-
immunoprecipitation assays. Coupling between G16 and different categories of receptors was
impaired by the mutations, with the effect of switch III mutations being more pronounced than
those in the α3 helix. Mutations of both clusters almost completely abolished the receptor coupling
and prevent receptor-induced Gβγ release.
Conclusion: The integrity of the switch III region and α3 helix of Gα16 is critical for the activation
of PLCβ, STAT3, and JNK but not ERK or NF-κB. Binding of Gα16 to PLCβ2 or TPR1 was reduced
by the mutations of either cluster. The same region could also differentially affect the effectiveness
of receptor coupling to G16. The studied region was shown to bear multiple functionally important
roles of G16.
Background
As the major group of cell-surface detectors for hormones
and neurotransmitters, G protein-coupled receptors
(GPCRs) employ a variety of signal transduction path-
ways to regulate cellular functions. One of the primary sig-
naling routes initiated upon activation of GPCRs is
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through the stimulation of PLCβ by members of the Gαq
subfamily. PLCβ activity can in turn regulate many down-
stream kinases and transcription factors, thereby modu-
lating cellular processes such as growth and
differentiation. The interactions between PLCβ and Gαq
subfamily members have been examined by mutagenesis
studies. Alanine scanning mutagenesis of Gαq has identi-
fied a stretch of amino acids (Ile217-Lys276) that may be
responsible for PLCβ interaction. Within this region, two
groups of amino acids (Asp243, Asn244, Glu245 and Arg256,
Thr257; Figure 1A and 1B) have been suggested to be cru-
cial for PLCβ interaction [1]. These two clusters of amino
acids are located in the α3 helix and β4-α3 loop (Figure
1A) which exhibits dramatic conformational changes dur-
ing G protein activation [2,3].
Gα16 is a member of Gq subfamily which can activate
PLCβ [4], and its unique promiscuity for GPCRs [4] high-
lights its importance in cellular signaling, especially in
hematopoietic cells where it is restrictively expressed [5].
Recent studies have revealed that Gα16possesses addi-
tional signaling properties which may be independent of
PLCβ activity. It has been demonstrated early on that
interleukin-2 and interleukin-8 induce Gα16-mediated
activation of ERK [6]. The use of a constitutively active
mutant of Gα16 (Gα16QL) confirmed that it can indeed
stimulate the activities of ERK [7] and JNK [8,9] in various
cell types. Presumably these stimulatory signals proceed
via PLCβ which triggers the cleavage of phosphatidyli-
nositol bisphosphate to form IP3 and DAG, and the latter
can modulate numerous signaling cascades through the
activation of protein kinase C (PKC). The ability of
Gα16QL to activate transcription factors such as STAT3
[7,10] and NF-κB [11,12] also requires PLCβ activity. The
discovery of a novel binding partner of Gα16, tetratr-
icopeptide repeat 1 (TPR1) [13] opens up new possibili-
ties for the regulation of ERK and its downstream
effectors. Since TPR1 prefers to bind to active Ras, its asso-
ciation with Gα16 may facilitate signaling along the Ras/
Raf-1/MEK/ERK axis. However, no study has yet addressed
the relative contributions of the PLCβ and TPR1 on the
G16-mediated signaling events.
Although Gα16 shares only 55% identity to Gαq in the
amino acid sequence, the two clusters of putative PLCβ-
interacting residues can be found in the homologous
regions of Gα16. Cluster 1 includes Asn246, Gln247 and
Glu248, while cluster 2 consists of Gly259 and Thr260. It is
noteworthy that both the glutamate and threonine at the
end of each cluster are highly conserved among the Gq
subfamily members (Figure 1A). Mutations of these resi-
dues may impair PLCβ activation, and affect other down-
stream effectors which are dependent on PLCβ activity.
Signals channeled through the TPR1/Ras route are
unlikely to be affected by such mutations unless TPR1 and
PLCβ interact with similar regions on Gα16. To date, the
TPR1-interacting domain(s) of Gα16 has not been defined.
Indeed, there are precedents for multifunctional domains
in Gα subunits. The receptor- and effector-interacting
regions (e.g., α2-β4, α3-β5, and α4-β6 loops) in Gαs and
Gαi subunits have substantial overlaps ([14-20], also see
Figure 1B). Therefore, it would be necessary to examine
the possible impacts of these five residues on the ability of
Gα16 to interact with different molecular partners. Fur-
thermore, both the switch III region and α3 helix show
substantial spatial rearrangements during the activation
of a Gα subunit, mutations in these two regions may also
perturb the receptor-mediated G protein activation.
In this study, the functional impacts of the two clusters of
amino acids were investigated for receptor-dependent and
independent regulation of different effectors of Gα16. The
results suggested that the two regions of interest were
important for the activation of PLCβ, STAT3, JNK but not
ERK or NF-κB. Besides, interactions of Gα16 with TPR1
and PLCβ were also reduced in a similar fashion. The
same regions could also differentially affect the effective-
ness of receptor coupling to G16.
Results
Design and expression of the Gα16 mutants
A previous study has shown that the residues lying on the
switch III region and the α3 helix of Gαq are required for
interaction with PLCβ [1]. The corresponding two clusters
of amino acids on Gα16 are Asn245-Glu247 and Gly259-
Thr260 (Figure 1A). Mutations of these two clusters of res-
idues into alanine created 3 mutants (Figure 2A) denoted
as 3A (Asn245-Glu247 → Ala), 2A (Gly259-Thr260 → Ala) and
5A (all 5 residues → Ala). The Gln212 → Leu (QL) muta-
tion [8,21] was also introduced to individual alanine
mutants to generate a constitutively active phenotype for
studying effector interactions in a receptor-independent
fashion. Previous studies have already confirmed the
capability of Gα16QL to activate various downstream
effectors such as ERK, NF-κB, STAT3 and JNK [7,12].
Since COS-7 cells do not express Gα16 endogenously, they
are an excellent platform for studying Gα16-regulated sig-
naling pathways by over-expressing Gα16 or its mutants. A
tailor-designed antiserum [22] which recognizes the N-
terminus (amino acid resides 13–27) of Gα16 was used for
detecting the expression level of Gα16 and its mutants.
Upon expression in COS-7 cells, a single band at around
43 kDa was detected by the anti-Gα16 antiserum for each
construct (Figure 2B, lower part). Plasma membrane pro-
teins prepared from non-transfected COS-7 cells served as
a negative control (Figure 2B, leftmost lane). All of the
mutants were expressed in COS-7 cells in a comparable
level as Gα16 and Gα16QL, indicating that the mutationsJournal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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Sequence alignment and molecular model of Gα16 Figure 1
Sequence alignment and molecular model of Gα16.(A) The sequences corresponding to the switch III region and α3 
helix of various Gα's were aligned. The consensus sequences are indicated as asterisks, colons and dots for strictly conserved, 
closely related and barely related residues among the candidates. The regions corresponding to the two clusters of putative 
PLC-interacting residues of Gαq are highlighted in orange. (B) A stereogram of the constructed molecular model of Gα16 is 
shown. Portions of the molecular surface were colored as blue, grey and cyan for the regions interacting with receptor, effec-
tor, or both, respectively, based on the studies of different G proteins. The side chains of the residues studied here are shown 
in spheres as indicated (except for Gly259 which is devoid of any side chain).Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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introduced did not affect the apparent expression or sta-
bility of Gα16.
Impairment of PLCβ Regulation
The same sets of transfected cells examined in expression
study were tested for their ability to stimulate PLCβ.
Expression of Gα16QL in COS-7 cells significantly
increased IP formation by ~7 fold as compared to cells
expressing wild-type (WT) Gα16. Expression of constitu-
tively active counterparts of the mutants (2A-QL, 3A-QL
and 5A-QL) in COS-7 cells significantly increased IP accu-
mulation as compared to the responses of their corre-
sponding non-QL counterparts. Responses induced by QL
forms of the mutants were significantly reduced as com-
pared with the response elicited by Gα16QL (Figure 2B).
2A-QL and 3A-QL retained 42% and 73% of the IP pro-
duction of Gα16QL, respectively, whereas 5A-QL pre-
served about 61% of the IP accumulation of Gα16QL.
Effects of 2A, 3A and 5A mutations on Gα16-mediated PLCβ activation Figure 2
Effects of 2A, 3A and 5A mutations on Gα16-mediated PLCβ activation. (A) Positions of the alanine mutations on the 
corresponding Gα16 mutants were shown as an alignment with the Gα16 sequence. Identical residues were simplified with dots. 
(B) Top: COS-7 cells were transiently transfected with 0.25 μg/ml cDNAs encoding the wild type or QL mutants of Gα16, 2A, 
3A and 5A. Transfectants were labeled with [3H]myo-inositol and assayed for IP accumulation. * IP accumulation stimulated by 
constitutively active mutants was significantly higher than that obtained with their wild type counterparts; ‡ Constitutive activ-
ity was significantly lower than that obtained with Gα16QL; Tukey-Kramer's test, p < 0.05. Bottom: Transfected COS-7 cells 
were harvested and membrane proteins were extracted for immunodetection. A Gα16-specific custom antiserum was used for 
recognition of Gα16 and its mutants. Fluorographs were visualized with the ECL chemiluminescence detection kit. Untrans-
fected COS-7 cells served as the negative control. Two separate sets of transfected cells yielded similar results. (C) COS-7 
cells were transfected with increasing amounts of cDNA encoding Gα16QL, 2A-QL, 3A-QL or 5A-QL. Empty vector pcDNA3 
was added to balance the amount of cDNA used in the transfection for each sample. Gα16-transfected cells served as the neg-
ative control (hollow square). Top: IP production increased dose-dependently with increasing expression levels of the constitu-
tively active form of alanine mutants and Gα16. Bottom: Expression level of constitutively active counterparts of Gα16 and its 
mutants were determined by Western blotting.Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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However, the differences between the mutants were not
statistically significant. Apparently, the results indicated
that the mutations partially impaired the ability of Gα16 to
activate PLCβ.
Further experiments were carried out to verify the
observed variations of the induced IP formation between
different constitutively active mutants. Increasing
amounts of individual QL mutant cDNA were transfected
into COS-7 cells and the IP accumulation in the trans-
fected cells were measured. For all of the QL mutants,
increasing levels of IP accumulation were observed as the
cDNA amounts were increased (Figure 2C, upper part).
The expression levels of individual QL mutants were cor-
respondingly increased as examined by Western blotting
(Figure 2C, lower part). There were obvious differences in
the PLCβ responses induced by the different mutants.
Gα16QL and 2A-QL induced maximal stimulation of IP
production at ~0.1 μg/ml, while maximal responses for
3A-QL and 5A-QL were only obtained at cDNA concentra-
tions of 0.5 μg/ml or higher. Despite similar levels of
expression, the maximal response stimulated by 2A-QL
was only about half of that elicited by Gα16QL. The esti-
mated EC50 values of IP accumulation were 0.020, 0.039,
0.123 and 0.610 μg/ml for Gα16QL, 2A-QL, 3A-QL and
5A-QL, respectively. These results indicate a progressive
decrease of the efficiencies for activating PLCβ when one
or more of the putative PLCβ-interacting domains on
Gα16 were mutated to alanine. Mutations at the α3 helix
(2A) might be particularly detrimental to PLCβ activity,
because the maximal stimulatory response of 2A-QL was
always lower than those of Gα16QL and the other two
alanine mutants. Since 5A-QL could attain a higher maxi-
mal PLCβ response than 2A-QL, the incorporation of 3A
mutations in the switch III region apparently relieved the
functional impairment associated with the 2A mutations
in the α3 helix of Gα16.
Differential Regulations of Downstream Effectors
Diverse downstream effectors have been found to be reg-
ulated by Gα16, including ERK, STAT3, NF-κB and JNK
[7,9,11,23], but their dependencies on PLCβ activation
have not been well defined. To further investigate the
functions of the selected amino acids in regulating these
downstream effectors, WT and QL forms of Gα16 and the
three mutants were examined for their regulations of these
downstream effectors when expressed in HEK293 cells.
We employed HEK293 cells in this part of the study
because of the regulations of ERK, STAT3, and NF-κB had
been fully characterized in this cellular background [7,11]
and all of the mutants could be efficiently expressed in
these cells (data not shown). As illustrated in Figure 3A,
no observable alteration in the total ERK1/2 levels was
found in cells transfected with different cDNA constructs.
The induction of ERK phosphorylation by the QL forms of
the alanine mutants was significantly higher than their
corresponding WT controls, and they were all similar to
Gα16QL. It should be noted that 2A-QL and 5A-QL con-
sistently generated a slightly lower level of ERK phospho-
rylation than 3A-QL and Gα16QL.
As both PLCβ and ERK can serve as upstream regulators of
STAT3 [7], we examined the ability of the mutants to
induce STAT3 Tyr705 phosphorylation. All three mutants
were capable of stimulating STAT3 phosphorylation at
Tyr705 albeit weaker than that induced by Gα16QL (Figure
3B). The phosphorylation triggered by 2A-QL, 3A-QL and
5A-QL were not significantly different between each
other. Given that Gα16QL-induced STAT3 phosphoryla-
tion involves PLCβ and PKC [7], these results were not
surprising because the alanine mutants have impaired
PLCβ regulation (Figure 2).
Regulation of NF-κB by Gα16 has been demonstrated in
recombinant systems as well as in human lymphoblast-
oma REH cells [11]. The phosphorylation of NF-κB
induced by constitutively active alanine mutants was
examined. As compared to Gα16, the expression levels of
total NF-κB were unaffected in cells transfected with the
alanine mutants (Figure 3C). The levels of NF-κB phos-
phorylation caused by the constitutively active alanine
mutants were only slightly reduced (but not statistically
different) when compared to the Gα16QL responses.
There was also no obvious difference between 2A, 3A and
5A mutants.
Since the background phosphorylation of JNK in trans-
fected HEK293 cells are relatively high (Chan AS and
Wong YH, unpublished observation), in vitro kinase assay
was adopted to determine the activity of JNK activity in
COS-7 cells instead. COS-7 cells were co-transfected with
Gα16 mutants together with HA-tagged JNK. The expres-
sion level of HA-tagged JNK were similar in all transfected
cells (Figure 3D). Gα16QL enhanced JNK-mediated [32P]-
labeling of GST-c-Jun significantly by 3.6-fold as com-
pared to that of Gα16. Surprisingly, none of the constitu-
tively active alanine mutants was capable of inducing JNK
activation (Figure 3D). It appeared that the sequence
integrity on the switch III region and α 3 helix is more crit-
ical for the regulation of JNK activation.
Differential Associations with PLCβ and TPR1
As the alanine mutations of the two clusters caused reduc-
tion of PLCβ activation, one of the possible explanations
would be the impairment of cognate recognition of PLCβ.
Co-immunoprecipitation experiments were performed to
study the possible alteration of the mutants and PLCβ2, a
PLCβ isoform commonly expressed and known to interact
with different Gq family members (Figure 4A). Expression
levels of different Gα16 constructs were similar when co-Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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Role of Gα16 mutants in STAT3, ERK1/2, NF-κB and c-Jun phosphorylation Figure 3
Role of Gα 16 mutants in STAT3, ERK1/2, NF-κB and c-Jun phosphorylation. HEK293 cells were transfected with 
pcDNA3, wild type or QL mutants of Gα16, 2A, 3A or 5A. The transfectants were deprived of serum overnight, and cell lysates 
were prepared for SDS-PAGE separation. Phosphorylated form or native ERK1/2 (A), STAT3 (B), and NF-κB (C) were 
detected by Western blotting as indicated. (D) For measuring Gα16-triggered JNK activity, COS-7 cells were transiently trans-
fected with each of the constructs mentioned together with a plasmid encoding HA-tagged JNK. Serum starvation was per-
formed as mentioned and JNK assay was performed as described in Methods. Expression of tagged JNK was determined by 
anti-HA antibody. The activation of JNK was monitored by detecting the phosphorylation of GST-fused-cJun. The fold induc-
tion of the phosphorylation of various effectors were quantified and plotted on the right hand side for comparisons. * QL 
counterparts of the mutants stimulate phosphorylation of the detected proteins significantly over cells expressing wild type 
complements (Tukey-Kramer's test, p < 0.05). ‡ QL counterparts of 2A-, 3A- and 5A-stimulated phosphorylation were signifi-
cantly lower than that of Gα16QL (Tukey-Kramer's test, p < 0.05).Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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The alanine mutants co-immunoprecipitate with TPR1 and PLCβ2 Figure 4
The alanine mutants co-immunoprecipitate with TPR1 and PLCβ2. (A) HEK293 cells were co-transfected with 
PLCβ2 and the Gα constructs as indicated at the bottom of the blots. Total cell lysates (TCL) from each condition were sub-
jected to immunoprecipitation using either anti-PLCβ2 or anti-Gα16 antiserum followed by protein G-agarose. Well-washed 
immunoprecipitates were subjected to SDS-PAGE and the proteins of interest were detected using specific antibodies as indi-
cated. TCL were separately run on blots for detecting the corresponding protein expressions. Two separate sets of trans-
fected cells yielded similar results. (B) Similar procedures were applied for detecting the interaction between Flag-tagged TPR1 
and the Gα constructs as indicated. TCL were subjected to immunoprecipitation using either anti-Flag agarose gel or anti-Gα16 
antiserum followed by protein G-agarose. Two separate sets of transfected cells yielded similar results. Band intensities were 
quantified and figures on the lanes of QL mutants are the fold increase compared with the band on the lane of their corre-
sponding wild-type counterparts.Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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expressed with recombinant PLCβ2, as revealed in the
total cell lysates. The endogenously expressed PLCβ2
could be detected (lane 1 of the bottom strip in Figure 4A)
but the level was too low for co-immunoprecipitation
assays. Both Gα16 and Gα16QL could be precipitated with
PLCβ2 using either anti-Gα16 or anti-PLCβ2 antibodies,
while Gα16QL showed much stronger interaction, indicat-
ing that the activation of Gα16 facilitated its interaction
with PLCβ2. Similarly, the QL forms of either one of the
three mutants showed better interactions with PLCβ2
when compared with their corresponding wild-type
forms. However, the fold increases between the three
alanine mutants and their corresponding QL forms were
much lower than the Gα16 pair (values on top of each lane
as indicated in Figure 4A). Such reduction was apparently
due to the slight enhancement of the interactions between
the alanine mutants and PLCβ2 as compared with Gα16.
No significant difference of the fold changes was observed
between the three mutant pairs. Nonetheless, the results
clearly indicated that the Gα16/PLCβ interaction was
impaired by both clusters of alanine mutations.
One of the distinctive features of Gα16-mediated signaling
is the association with TPR1, which facilitates the accumu-
lation of active Ras [13] and in turn activate the Raf/MEK/
ERK cascade. To study the impact of the alanine mutations
on the interaction between Gα16 and TPR1, a Flag-tagged
full-length TPR1 was co-expressed with each of the Gα16
constructs as indicated in Figure 4. Co-immunoprecipita-
tion of the proteins of interest was performed using anti-
Flag tag or anti-Gα16 antibodies. Both Gα16 and Gα16QL
could be co-immunoprecipitated with TPR1 (Figure 4);
Gα16QL was bound to TPR1 more efficiently under our
experimental condition. A truncated form of TPR1 lacking
the C-terminal tail did not bind to Gα16 (Rico K. Lo,
Andrew M. Liu and Yung H. Wong, data not shown). The
three alanine mutants could also be co-immunoprecipi-
tated with TPR1. Similar to the Gα16-PLCβ2 interactions,
the QL versions of the alanine mutants showed stronger
interactions with TPR1 than their corresponding non-
active counterparts. Fold enhancements between the QL
form of the alanine mutants and the non-active forms
were weaker than Gα16 pair. The 5A-QL mutant showed
the weakest enhancement of TPR1 interaction. Expression
levels of 5A and 5A-QL might be less in the experiment as
showed in the total cell lysates, but the fold enhancement
was still the least among the others. More obvious results
were obtained when the TPR1-Gα16  complexes were
immunoprecipitated with anti-Gα16 antibody. The results
suggested that the interactions between TPR1 and Gα16
were also dependent on the identities of the two amino
acid clusters. Alanine mutations at both clusters caused
the greatest reduction of the interaction.
Perturbation of Receptor-Mediated Regulation of PLCβ
G16 is well-known for its receptor coupling promiscuity
[4], but it also exhibits different degrees of coupling effi-
ciencies to various GPCRs [22,24]. Since the receptor- and
effector-interacting domains overlap partially on the sur-
face of Gα subunits, it is possible that the alanine muta-
tions can also affect the receptor coupling of Gα16. To test
this possibility, a panel of GPCRs was examined for their
functional coupling to Gα16 and the alanine mutants
using the IP accumulation assay. These GPCRs included
Gi-coupled adenosine A1  receptor (A1R), complement
C5aR receptor, formyl peptide receptor (fMLPR), and the
Gs-coupled adenosine A2A and A2B receptors (A2AR, A2BR)
and dopamine D1 receptor (D1R). All of these receptors
are capable of utilizing Gα16 to elicit intracellular calcium
mobilization in FLIPR assays [24].
The selected Gi- or Gs-coupled receptors all induced IP
accumulation significantly in the presence of Gα16, but
with variable efficiencies (Figure 5). These receptors were
also capable of interacting with the alanine mutants. In
general, IP accumulation mediated by 2A and 3A were
~50% and 35%, respectively, of that induced by Gα16. In
some cases, such as C5aR and A2AR, the differences
between the responses of 2A and 3A mutants were not sig-
nificant, but it may be due to the weaker overall responses
when compared with other receptors. Contrastingly, the
differences between the phenotypes of these two mutants
in the coupling to A1R, A2BR and D1R were more obvious
(≥ 50%). Differences in the absolute responses of various
receptors have been demonstrated previously in the meas-
urement of intracellular Ca2+ mobilization (see Table 1 of
[24]). The differential coupling efficiencies of the tested
GPCRs with G16 allowed us to detect the differences on
GPCR coupling between the alanine mutants. Agonist-
induced activation of 5A could only marginally increase
IP accumulation in cases of A1R, fMLPR and D1R, while
the other receptors were totally unable to elicit a response
via 5A (Figure 5). The defective phenotype indicated that
the two clusters were essential for the effective receptor-
mediated PLCβ activation through Gα16. The switch III
region (harboring the 3A mutations) appeared to be more
influential to the productive receptor coupling events
than the α 3 helix.
Upon closer examination of the basal levels of the cells
expressing Gα16 or the 3 mutants, it was noticed that the
basal levels of IP accumulation in the cells expressing A1R,
A2AR or A2BR with Gα16 were higher than with the mutants
(Figure 5). This trend of decreasing basal IP accumulation
was similar to the receptor-activated responses, with
Gα16>2A>3A>5A. The results here showed that the basal
activities of all three adenosine receptors were suppressed
by the expression of the alanine mutants, particularly for
5A. Such evidence further implied that the alanineJournal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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Coupling of alanine mutants of Gα 16 to different categories of G protein-coupled receptors Figure 5
Coupling of alanine mutants of Gα 16 to different categories of G protein-coupled receptors. Individual GPCRs 
were coexpressed with Gα16, 2A, 3A or 5A in COS-7 cells. Transfected cells were labeled with [3H]myo-inositol and treated 
with PTX overnight. Cells were then treated with the appropriate receptor agonists (1 μM CHA for A1R, 100 nM C5a for 
C5aR, 100 nM fMLP for fMLPR, 10 μM adenosine for both A2AR and A2BR, 10 μM dopamine for D1R) for an hour before 
extraction of accumulated labeled IP. *Agonist significantly stimulated IP production as compared to their corresponding 
untreated counterparts; Tukey-Kramer's test, p < 0.05. ‡ Agonist-induced responses in mutant-expressing cells were signifi-
cantly lower than that obtained with Gα16; Tukey-Kramer's test, p < 0.05.Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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mutants might associate with the receptors, but such
receptor-G protein complexes were defective and the
mutants actually sequestered the spontaneous activities of
the receptors (also see Discussion).
5A Mutant was Defective in Receptor-Mediated 
Regulation of Type II Adenylyl Cyclase
Type 2 adenylyl cyclase (AC2) can be synergistically stim-
ulated via the Gβγ complex released from Gα in the pres-
ence of activated Gαs  [25,26]. Measurement of AC2-
mediated cAMP production in such circumstance is useful
for the detection of receptor-mediated release of Gβγ sub-
units. Functional interaction of the alanine mutants with
Gi-coupled receptors, if any, would be expected to stimu-
late AC2 upon agonist triggering. HEK293 cells were co-
transfected with empty vector pcDNA3 and cDNAs encod-
ing GαsQL, fMLPR and AC2. Activation of the fMLPR
resulted in the stimulation of endogenous Gi and release
Gβγ which led to the activation of AC2 (Figure 6). PTX
pretreatment attenuated the corresponding increase of
cAMP level. In cells co-expressing Gα16, GαsQL, fMLPR
and AC2, activation of fMLPR led to an increase in cAMP
formation in a PTX-insensitive manner (Figure 6), indicat-
ing the functional coupling of fMLPR with Gα16. Both 2A
and 3A mutants exhibited comparable significant
increases in cAMP production as Gα16. However, 5A was
totally incapable of stimulating AC2, which suggested that
the receptor-mediated activation of G16 and the subse-
quent Gβγ release might be severely impaired by the
mutations on both switch III and α 3 helix.
Discussion
There are at least two paths through which Gα16 can trans-
mit signals to downstream effectors, via PLCβ or TPR1.
Their relative contributions to well-established down-
stream effectors such as ERK, STAT3, NF-κB and JNK have
not been clearly addressed. This study attempted to deci-
pher the differential roles of the two streams of signals by
mutating putative "PLCβ-interacting" residues on switch
III and α 3 helix of Gα16. All three mutants (2A, 3A, and
5A) exhibited impaired ability to stimulate PLCβ. Differ-
ential regulations of ERK, STAT3, NF-κB and JNK by the
mutants have been observed, suggesting that Gα16 regu-
lates these downstream signals through overlapping but
discrete pathways. Interactions between the mutants and
PLCβ2 or TPR1 were reduced by the alanine mutations,
and mutations of both clusters caused the greatest reduc-
tion of interactions. Furthermore, the 5A mutant with
both clusters mutated was severely impaired in receptor
coupling, as was observed in receptor-mediated activation
of PLCβ and AC2, and the sequestration of constitutive
receptor activity. Collectively, this study provided evi-
dence that the integrity of the switch III region and α 3
helix of Gα16  was critical for both PLCβ-and TPR1-
dependent signaling events.
Gαq and Gα16 belong to the same subfamily of heterot-
rimeric Gα subunits and both regulate PLCβ in a similar
fashion. Presumably, the molecular interactions between
Gαq and Gα16 with PLCβ would share some common fea-
tures. Based on the previous study on Gαq [1], the five
homologous residues on Gα16 were mutated into alanine,
and the resultant mutants showed partial impairment on
PLCβ regulation (Figures 2). Employment of Q212L
mutation bypassed the possible influence on receptor
coupling as well as the effect of Gβγ complex release,
which may also activate PLCβ in its own. The incomplete
impairment suggests that the Gα-effector interactions may
involve multiple contact sites, as documented in the stud-
ies on other Gα subunits [15,17,18]. Co-immunoprecipi-
tation experiments showed that the physical association
between PLCβ and Gα16 was not completely abolished by
the mutations of either clusters (Figure 4). The mere asso-
ciation between the two proteins was apparently not suf-
ficient to exert the full activating effect. Mutants bearing
the 2A mutations on the surface of α 3 helix of Gα16 were
less effective in PLC activation (Figure 2). These two resi-
dues were more likely to contribute to the direct interac-
tion and activation of PLCβ, and so have a greater effect.
The switch III region where 3A mutations were located has
been suggested to influence the interdomain interactions
between the helical and GTPase domain of Gαs subunit,
which in turn affect the GTP-induced activation [27].
Assuming the activation mechanisms of the homologous
Gα subunits were very similar, the weaker suppression on
PLCβ activation by 3A mutations might be an indirect
effect. As all of the mutants were expressed to a compara-
ble level (Figure 2), the differences in PLCβ activation
could not be attributed to insufficient expression of a par-
ticular mutant.
We have previously proposed that Gα16QL-induced
STAT3 phosphorylation is mediated via c-Src/JAK and
ERK pathways, with PLCβ/PKC serving as upstream mod-
ulators [7,11]. Reduction of PLCβ activation caused by the
mutations may disturb the signaling cascades at multiple
points, and the modulation of downstream effectors may
be altered differentially depending on the strength of
upstream signals to be integrated. The present study
shows that the alanine mutants partially inhibited the
phosphorylation of STAT3 (Figure 3B), and the inhibitory
profiles are reminiscent of the PLCβ activities (Figure 2B).
However, the same mutants had very little effect on ERK
phosphorylation (Figure 3A). These results suggest that
Gα16QL-induced PLCβ signal is important for STAT3
phosphorylation, but not ERK phosphorylation. With the
discovery of TPR1, Gα16 may stimulate the Raf/MEK/ERK
axis through Ras. However, Ras-mediated activation of
ERK is not the only ERK-regulating signal. Other streams
of signals contributing to ERK activation include the
PLCβ-mediated Ca2+ mobilization and PKC activation, asJournal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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well as possibly c-Src and JAK [10,11]. Furthermore, vari-
ous molecular scaffolds for ERK pathway intermediates,
GRKs and other signaling components may also contrib-
ute to the specificity of the ERK regulation [28,29]
induced by the activation of Gα16, which have not been
rigorously studied here. The dependence of STAT3 activity
on ERK is somewhat controversial, because ERK has been
shown to negatively regulate STAT3 [30]. JNK, on the
other hand, appears to be necessary for Src-mediated acti-
vation of STAT3 [31]. In this regard, it is interesting to
note that all three mutants exhibited defective regulations
of JNK (Figure 3D). It remains to be determined if JNK/Src
signals are critical for the regulation of STAT3 tyrosine
phosphorylation.
Gα16QL is known to activate JNK in various cell types
[8,9]. The complete loss of the ability of all three alanine
mutants to stimulate JNK suggests that Gα16-induced
PLCβ activation is essential for this pathway. PLCβ-trig-
gered intracellular Ca2+ release can lead to the activation
of guanine exchange factors (e.g. Sos) for small G proteins
like Rac, which then activates JNK. The heavy dependence
of JNK on the Ca2+ signal has been previously demon-
strated: treatment of Ca2+ chelator BAPTA-AM completely
abolished the bradykinin-induced JNK activity in HepG2
cells [32]. Although the PLCβ activation was not com-
pletely attenuated by the alanine mutants, diminished
flux of intracellular Ca2+ might be already enough to sup-
press the JNK activity. Several studies from our laboratory
have shown that Gβγ complex is a mediator of JNK activa-
tion by various GPCRs [32-36], but such regulation is
abolished upon suppression of the Ca2+-activated SOS/
Rac pathway [32,33]. The preservation of ERK activation
did not alleviate the suppressive effects of the mutants on
Receptor-induced activation of type II adenylyl cyclase (AC2) mediated by Gα 16 and its mutants Figure 6
Receptor-induced activation of type II adenylyl cyclase (AC2) mediated by Gα 16 and its mutants. HEK293 cells 
were cotransfected with cDNAs encoding the AC2 (3 μg/ml), GαsQL (0.015 μg/ml) and fMLPR (3 μg/ml) together with Gα16, 
2A, 3A or 5A. Cells were labeled with [3H]adenine and treated with or without PTX (100 ng/ml) overnight. cAMP accumula-
tion was assayed in response to the treatment with 100 nM fMLP for 1 h. * cAMP accumulation was significantly increased as 
compared with their corresponding basal value; Tukey-Kramer's test, p < 0.05.Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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JNK activation, which further implied the distinctive reg-
ulatory mechanisms of ERK and JNK activation by Gα16.
Phosphorylation of NF-κB induced by Gα16 was much less
affected by the alanine mutations (Figure 3C). Regulation
of NF-κB activation is mainly through the IKK/IκB path-
way [12], and both Ca2+ and MAPKs play important regu-
latory roles on IKK/IκB activity. Apparently, PLCβ/Ca2+
signals did not play a dominating role in the NF-κB regu-
lation. The very similar profile of the activation of ERK
and NF-κB suggested that ERK might be the key regulator
of Gα16-mediated NF-κB activation. The essential role of
ERK on the regulation of NF-κB has been studied in other
cellular contexts [37,38]. The unique interaction of Gα16
with TPR1, which promotes the Ras-mediated ERK activa-
tion [13], might be one of the possible explanations. Var-
ious monomeric G proteins, including Ras and Rac1, can
activate NF-κB activity [39].
Mutations of both amino acid clusters resulted in almost
complete loss of GPCR-induced PLCβ activation. Consist-
ently, the effect of 3A mutation on the switch III region
appeared to be more detrimental than 2A on the α 3 helix,
and that seemed to be contrary to the QL mutants. The
apparent discrepancies may be due to the different func-
tional impacts of the two mutated clusters towards recep-
tor-mediated activation of Gα16  versus the mutation-
induced spontaneous activation of Gα16QL. It has been
shown previously that the intramolecular interactions
along the interface between the helical and GTPase
domains of Gαs, of which switch III is involved, is critical
for the receptor-mediated activation of Gαs [27,40]. The
impact of the mutations of switch III (i.e. 3A mutant)
could be revealed when studying the receptor-dependent
signaling events, like those in Figures 5 and 6. The results
indicated that Gα16 made use of similar molecular archi-
tecture as Gαs, wherein the alterations of the interdomain
interactions (3A mutant) exerted a greater effect on the
receptor-mediated activation than the mutations in the
middle of α 3 helix (2A mutant). However, in the pres-
ence of Q212L mutation (the constitutively active
mutant), Gα16 is simply 'locked' into a GTP-bound state
with certain intramolecular conformational adaptations.
Such behavior might mask the effect of 3A mutation on
the activation process of Gα16. Instead, the functional
defects caused by the mutations on the exposed surface
(2A mutant) became more prominent.
The co-expression of Gα16 and GPCRs often leads to an
elevated basal IP accumulation [4,24], presumably
because the spontaneous activity of receptors becomes
amplified through the formation of GPCR/Gα16  com-
plexes. Agonist-independent constitutive activation of
A1R [41,42] and A2AR [43,44] have been previously dem-
onstrated. Although not much evidence is available to
illustrate the constitutive activity of A2BR, inverse agonists
for A2BR have been identified [45]. Expression of the three
alanine mutants resulted in the reduction of the basal IP
accumulation, with the effect of 5A being the most prom-
inent, indicating that the G protein complex formed by
the alanine mutants reversed the constitutive activity of
the adenosine receptors. Such hypothesis is not over-spec-
ulative, as it has been shown that the affinity of Gs for β2-
adrenergic receptor can be increased by replacing 5 Gαs
residues in the α 3/β5 loop region with the homologous
Gαi2 residues [17]. Our previous study also showed that
Gα16/z chimeras exhibit robust constitutive activity when
co-expressed with various GPCRs [24], indicating that
Gα16 could associate with GPCR and transduce spontane-
ous receptor activity.
AC2 activation assay was employed to study the release of
Gβγ complex from coupled G protein after receptor activa-
tion (Figure 6). The assay readout is less sensitive to the
functional effect of Gα subunits, and hence mostly reflects
the efficiency of receptor-mediated Gβγ release from the
activated Gα subunit. One of our previous studies [21]
showed that mutations on Gα16 causing defective Gβγ
interaction significantly reduced its ability to stimulate
AC2. In this study, mutations of both but not either one
of the clusters destroyed the receptor coupling of Gα16 to
fMLP receptor. Defective functional release of Gβγ upon
receptor activation would suggest that the G protein
trimer could not transmit the proper conformational
changes from activated receptor or it could not even detect
the activated receptor. One possibility is that the pre-asso-
ciated receptor-G protein complex prefers to stay in an
inactivated and associated form, which is echoed by the
observation of the reduction of the constitutive receptor
activities of the adenosine receptors (Figure 6).
Conclusion
The two clusters of putative PLCβ-interacting residues on
Gα16 were indeed crucial for both receptor coupling and
regulation of various downstream effectors. The two resi-
dues on the α 3 helix were more exposed and important
for PLCβ activation, whereas the clusters of three residues
on the switch III region affected the receptor-mediated
activation of Gα16 more. Mutations of either clusters sup-
pressed the activation of STAT3 and, to a greater extent,
JNK activation but not ERK and NF-κB signaling. The
physical associations between Gα16 and PLCβ or TPR1
were sensitive to the mutations, and both clusters were
both determinative to the interactions. Further studies on
the functional impacts of the mutual interactions between
Gα16, PLCβ and TPR1 may provide more insights on the
characteristics of G16-mediated signaling events.
Methods
Materials
Human TPR1 cDNA was kindly provided by Richard D. Ye
(Department of Pharmacology, College of Medicine, Uni-Journal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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versity of Illinois, Chicago, IL). Human embryonic kidney
293 (HEK293) and monkey kidney fibroblast COS-7 cells
were purchased from American Type Culture Collection
(ATCC CRL-1573 and 1651). Restriction endonucleases
were from Roche Applied Sciences. DNA purification col-
umns were from Qiagen. DNA modification enzymes,
custom primers and cell culture and transfection reagents
were from Invitrogen. [3H]adenine and chemilumines-
cence detection kit for Western blotting were from GE
Healthcare. [γ-32P]ATP and [3H]myo-inositol was from
PerkinElmer Inc. Antibodies against various molecules are
from: Cell Signaling Technology (Danvers, MA, USA) for
ERK1/2 (Thr202/Tyr204), STAT3 (Tyr705) and NF-κB
(Ser536) and their total forms; Torrey Pines Biolabs (C-ter-
minus; Houston, TX, USA) and Gramsch Laboratories (N-
terminus, custom-made; Schwabhausen, Germany) for
Gα16; sc-206, Santa Cruz Biotechnology (Santa Cruz, CA,
USA) for anti-PLCβ2; anti-FLAG antiserum and anti-FLAG
affinity gel were from Sigma (St. Louis, MO, USA). Protein
G-agarose and cross-linking reagent dithiobis [succinimi-
dylpropionate] (DSP) were from Pierce Biotechnology
(IL, USA). Pertussis toxin was purchased from List Biolog-
ical Laboratories. All other chemicals were obtained from
Sigma.
Sequence alignment and molecular modeling
Complete amino acid sequence alignment of Gα 's was
generated by CLUSTAL X 1.83 [46]. Molecular models
were created by SWISS-MODEL web server [47] using the
coordinates of the crystal structures of Gαi1 [48] and Gαt1
[49] in their corresponding heterotrimers retrieved from
Protein Data Bank maintained by Research Collaboratory
for Structural Bioinformatics [50] as the modeling tem-
plates. The model was modified and visualized with UCSF
Chimera [51].
Construction of Gα16 Mutants
Polymerase chain reactions (PCR) were performed to con-
struct the mutants. Amplified cDNA fragment was sub-
cloned into pcDNA3 vector, which possessed T7 and SP6
promoter regions for primer attachment in PCR reaction.
Human Gα16WT and Gα16QL [21] were used as a tem-
plate to amplify mutants. A pair of overlapping sense and
anti-sense primers was designed encoding the desired
mutations to replace particular amino acids into alanines.
Primers are listed (from 5' to 3') with the mismatch nucle-
otides underlined: 16-2A/S: CTC GCA TTG TTT GCG GCG
ATC CTG GAA CTA CCC; 16-2A/AS: TTC CAG GAT CGC
CGC AAA CAA TGC GAG GCT; 16-3A/S: GAG GAG AAC
GCA GCT GCA AAC CGC ATG AAG GAG; 16-3A/AS: CAT
GCG GTT TGC AGC TGC GTT CTC CTC CAG GCA. The
corresponding cDNA fragments were amplified using the
desired primers with either T7 or SP6 primer by thermal
cycling at 94°C (60 sec)/53°C (60 sec)/72°C (90 sec) for
35 cycles in Thermocycler 40 from Stratagene. Subse-
quently, the two fragments were pooled together as tem-
plates and the full-length mutated cDNAs were generated
with the flanking (T7 and SP6) primers. The same thermal
cycle program was used for second PCR to amplify full-
length products. Full-length PCR products were sub-
cloned in Xba  I site of pcDNA3. DNA sequences of
mutants were verified by autosequencing using BigDye®
Terminator v3.1 cycle sequencing kit and ABI PRISM®
Genetic Analyser (Applied Biosystems) and restrictive
enzyme digestion. 5A and 5A-QL were constructed by
using 3A and 3A-QL as templates, respectively.
Cell Culture and Transfection
HEK293 and COS-7 cells were cultured in Earle's modi-
fied essential medium (MEM) and Dulbecco's modified
Eagle's medium (DMEM), respectively, with 10% fetal
bovine serum (FBS; vol/vol), 50 units/ml penicillin and
50 μg/ml streptomycin. Cells were incubated at 37°C in
humidified air with 5% CO2. At the day before transfec-
tion, COS-7 cells were seeded on 12-well plates at a den-
sity of 1 × 105  cells/well. For western blot analysis,
HEK293 cells were used instead, wherein 2 × 105 cells
were seeded on 6-well plates. For adenylyl cyclase assay, 4
× 105 of HEK293 cells were transferred to 12-well plates.
For c-Jun N-terminal kinase assay, 3 × 105 of COS-7 cells
were seeded on 6-well plates. cDNA transfection was
achieved using Lipofectamine™ and PLUS™ reagents fol-
lowing the manufacturer's protocol. 50–75% of the cell
population will take up the cDNAs as indicated by co-
expressing β-galactosidase as a reporter.
Inositol Phosphate (IP) Accumulation Assay
750 μl of inositol-free DMEM containing 5% FBS and 2.5
μCi/ml myo-[3H]-inositol was added to each well of trans-
fected COS-7 cells and incubated for 18–24 hr. The labe-
ling media were subsequently replaced by 1 ml of assay
medium (DMEM with 20 mM Hepes, pH 7.5 and 10 mM
LiCl) for 10 min and then 1 ml of assay medium contain-
ing the appropriate agonist was added to the cells for
another 1 h at 37°C. Reaction was stopped by adding 750
μl of ice-cold 20 mM formic acid after aspiration and the
plates were stored at 4°C for 30 min. [3H]-IP were sepa-
rated from labeled inositol by ion-exchange chromatogra-
phy as described previously [52].
cAMP Accumulation Assay
HEK293 cell were labeled with [3H]-adenine (1 μCi/ml)
in MEM containing 1% FBS (vol/vol) one day after trans-
fection. After 18–24 h the labeling media were replaced by
1 ml of 20 mM Hepes-buffered MEM containing 1 mM
isobutylmethylxanthine (IBMX) and the appropriate
drugs and incubated at 37°C for 30 min. The treatment
was terminated with 1 ml ice-cold 5% trichloroacetic acid
(wt/vol) with 1 mM ATP after aspiration and stored at 4°C
for 30 min. [3H]cAMP was extracted from the pool ofJournal of Molecular Signaling 2008, 3:17 http://www.jmolecularsignaling.com/content/3/1/17
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labeled nucleotides by sequential ion-exchange chroma-
tography as described [53].
Data Analysis
For cAMP and IP accumulation assay, absolute values for
cAMP or IP accumulations varied between experiments,
but variability within a given experiment was in general
<10%. The cAMP levels were interpreted as the ratios of
the counts per minute of [3H]cAMP fractions to those of
the total labeled nucleotide fractions and expressed as
cAMP/(cAMP + Total). Similarly, IP levels were expressed
as IP/(IP + Total). Data shown in the figures were the
mean ± S.D. of triplicates within one single experiment. At
least three individual experiments yielded similar results.
One-way ANOVA with Tukey-Kramer's test were per-
formed using GraphPad Prism 3.03 to verify the signifi-
cance between different treatment groups within the
experiments.
Cross-linking and Coimmunoprecipitation
Transfected HEK293 cells were washed with PBS twice and
then treated in the same buffer containing 0.5 mM DSP
for 15 min at room temperature to cross-link the mem-
brane proteins. Cells were washed as above and main-
tained in quenching solution (50 mM glycine in PBS, pH
7.4) for 5 min, and then lysed in RIPA buffer (25 mM
HEPES, pH 7.5, 0.1% SDS, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 1 mM dithiothreitol, 200 μM
Na3VO4, 0.7 μg/ml pepstatin, 4 μg/ml aprotinin, 100 μM
PMSF, and 2 μg/ml leupeptin). For coimmunoprecipita-
tion, cell lysates were incubated with anti-Gα16 (4 μg/sam-
ple) or anti-PLCβ2 antiserum (0.4 μg/sample), followed
by the incubation with 30 μl of protein G-agarose (50%
slurry) at 4°C for 2 h, or 30 μl anti-FLAG affinity agarose
gel (50% slurry) at 4°C overnight. Immunoprecipitates
were washed by 400 μl RIPA buffer 4 times, and then
resuspended in 50 μl RIPA buffer gel loading buffer and
boiled for 5 min. Gα16 and FLAG-TPR1 proteins in the
immunoprecipitates were detected by specific primary
antisera and horseradish peroxidase-conjugated second-
ary antisera using Western blotting analysis.
Western Blotting Analysis
COS-7 cells were grown on 100-mm dishes to 70–80%
confluence. Transfection was performed as in 12-well
plates with proper adjustments to the surface area of the
plate and the amounts of the reagents used. After 48 h in
normal growth conditions, cells were washed with Ca2+/
Mg2+-free Dulbecco's PBS (DPBS) and harvested with 3 ml
DPBS containing 10 mM EDTA. The following procedures
were performed at 4°C. Cells were spun down briefly
(200 g, 5 min), resuspended in hypotonic lysis buffer and
lysed by one cycle of freeze-thawing followed by 10 pas-
sages through a 27-gauge needle. Nuclei were removed by
brief spinning and membranes were collected by spinning
the supernatants at 15,000 g for 15 min. Membrane pel-
lets were finally resuspended in lysis buffer. Detergent-
compatible protein assay system (Bio-Rad) was employed
to determine the protein contents in cell lysates or crude
membrane preparations. Protein samples were separated
by 10% SDS-PAGE. Separated proteins were transferred to
nitrocellulose membrane by electroblotting. Antisera
against specific proteins were applied and the detection
was facilitated by ECL chemiluminescence reagents (GE
Healthcare). Band intensities on the autoradiographs
were analyzed and quantified using ImageJ 1.40 [54].
In vitro c-Jun N-terminal Kinase (JNK) Assay
Details of the assays were basically identical as described
in our previous study [55]. Briefly, COS-7 cell were trans-
fected with the appropriate constructs and serum-starved
overnight before assay. Cells were lysed by chilled deter-
gent-containing lysis buffer with agitation on ice. 50 μl of
each supernatant was used for the detection of JNK-HA
expression after removing the cell debris by centrifuga-
tion, and the remaining was incubated for 1 h at 4°C with
anti-HA antibody (2 μg/sample), followed by incubation
with 30 μl of protein A-agarose at 4°C for 1 h. Immuno-
precipitates were washed twice with lysis buffer and twice
with kinase assay buffer, resuspended in kinase assay
buffer with 5 μg of GST-c-Jun, and the kinase reactions
were initiated by the addition of 10 μl of ATP buffer (50
μM ATP containing 2 μCi of [γ-32P]-ATP per sample). After
30 min incubation at 30°C with occasional shaking, the
reactions were terminated by adding sample buffer, and
the samples were resolved by 12% SDS-PAGE. The gel was
fixed for 30 min and the radioactivity incorporated to
GST-c-Jun was detected and quantified by PhosphorIm-
ager (Molecular Dynamics 445 SI).
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